SFX by Ex Libris Inc.

Title:	β-Sarcoglycan gene transfer decreases fibrosis and restores force in LGMD2E mice
Source:	Gene Therapy [0969-7128] Pozsgai, E R yr:2015

Basic

Full text

Full text available via Nature

Year:

Volume:

Issue:

Start Page:

Document delivery

Request document via Library/Bibliothek

Users interested in this article also expressed an interest in the following:
description	1.	Hacein-Bey-Abina, S. "LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1." Science 302.5644 (2003): 415-9.
description	2.	Kittiphong Paiboonsukwong, Fumi Ohbayashi, Haruka Shiiba, Emi Aizawa, Takayuki Yamashita, Kohnosuke Mitani;, K. "Correction of mutant Fanconi anemia gene by homologous recombination in human hematopoietic cells using adeno-associated virus vector." Journal of Gene Medicine 11.11 (2009): 1012-1019.
description	3.	Cideciyan, Artur V. "Mutation-independent rhodopsin gene therapy by knockdown and replacement with a single AAV vector." Proceedings of the National Academy of Sciences of the United States of America 115.36 (2018).
description	4.	Ahn, Sang-Joon J. "Effects of oxygen on biofilm formation and the AtlA autolysin of Streptococcus mutans." Journal of bacteriology 189.17 (2007): 6293-302.
description	5.	Cavazzana-Calvo, M. "Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1." The journal of clinical investigation 118.9 (2008): 3132-42.
description	6.	Calvo, M. "Gene Therapy of Human Severe Combined Immunodeficiency (SCID)-X1 Disease." Science 288.5466 (2000): 669-672.
description	7.	Paulk, Zhongya K. "Adeno-associated virus gene repair corrects a mouse model of hereditary tyrosinemia in vivo." Hepatology 51.4 (2010): 1200-8.
description	8.	Hacein-Bey-Abina, S. "Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy." New England Journal of Medicine, The 346.16 (2002): 1185-1193.
description	9.	Fang, J. "An Antibody Delivery System for Regulated Expression of Therapeutic Levels of Monoclonal Antibodies In Vivo." Molecular therapy 15.6 (2007): 1153-9.
description	10.	Gradinaru, Bin P. "Cre-dependent selection yields AAV variants for widespread gene transfer to the adult brain." Nature Biotechnology 34.2 (2016): 204-9.
description	11.	Mueller, Qing L. "MicroRNA-regulated, systemically delivered rAAV9: a step closer to CNS-restricted transgene expression." Molecular therapy 19.3 (2011): 526-535.
description	12.	Baum, C. "Chance or necessity? Insertional mutagenesis in gene therapy and its consequences." Molecular therapy 9.1 (2004): 5-13.
description	13.	Rabbitts, Terence H H. "Activation of the T-cell oncogene LMO2 after gene therapy for X-linked severe combined immunodeficiency." The New England journal of medicine 350.9 (2004): 913-22.
description	14.	Hattori, Y. "Nucleic-acid based gene therapy approaches for sepsis." European journal of pharmacology. 833: 403-410.
description	15.	Dworkin, J. "The Medium Is the Message: Interspecies and Interkingdom Signaling by Peptidoglycan and Related Bacterial Glycans." Annual review of microbiology 68.1 (2013): 137-154.
description	16.	Jung, C. "Streptococcus mutans autolysin AtlA is a fibronectin-binding protein and contributes to bacterial survival in the bloodstream and virulence for infective endocarditis." Molecular microbiology 74.4 (2009): 888-902.
description	17.	Lee, Y. "Inactivation of the Pseudomonas putida KT2440 dsbA gene promotes extracellular matrix production and biofilm formation." FEMS microbiology letters 297.1 (2009): 38-48.
description	18.	Kreth, J. "Characterization of Hydrogen Peroxide-Induced DNA Release by Streptococcus sanguinis and Streptococcus gordonii." Journal of bacteriology 191.20 (2009): 6281-6291.
description	19.	Dantzer, R. "From inflammation to sickness and depression: When the immune system subjugates the brain." Nature reviews. Neuroscience 9.1 (2008): 46-56.
description	20.	Rahiotis, C. "Effect of a CPP-ACP agent on the demineralization and remineralization of dentine in vitro." Journal of dentistry 35.8 (2007): 695-8.